<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599812447052</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599812447052</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Response to “Further Evidence of Oxymetazoline’s Safety in Otologic Surgery” from Glenn Isaacson</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Daniel</surname><given-names>Sam J.</given-names></name>
<degrees>MD, FRCSC</degrees>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0194599812447052">Departments of Otolaryngology–Head &amp; Neck Surgery and Pediatric Surgery, McGill University, Montreal Children’s Hospital, Montreal, Quebec, Canada Email: <email>Sam.daniel@mcgill.ca</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>147</volume>
<issue>1</issue>
<fpage>179</fpage>
<lpage>180</lpage>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>We wish to thank Dr Isaacson for his insightful comments on our publication<sup><xref ref-type="bibr" rid="bibr1-0194599812447052">1</xref></sup> and congratulate him on being a true leader in the use of oxymetazoline in otologic surgery. In fact, Dr Isaacson’s pioneering work in the field, and some of the concerns raised with regard to the potential danger of the vasoconstrictive effect of oxymetazoline, were part of the impetus for our experiments.<sup><xref ref-type="bibr" rid="bibr2-0194599812447052">2</xref><xref ref-type="bibr" rid="bibr3-0194599812447052"/>-<xref ref-type="bibr" rid="bibr4-0194599812447052">4</xref></sup></p>
<p>Oxymetazoline can be very useful in controlling bleeding during myringotomy and tympanostomy tube placement. Although this is rarely significant, bleeding can prolong the time of surgery as well as lead to blockage of the pressure-equalizing tube. Interestingly, the prophylactic use of adrenergic α-agonists to prevent the occurrence of blocked tubes was shown to be the practice of 13% of otolaryngologists in a recent survey. It is also the practice of several otolaryngologists at the Montreal Children’s Hospital, where to date more than 2000 ears have received oxymetazoline drops at the time of middle ear ventilation tube insertion without any adverse outcome.</p>
<p>In our study, we used our validated chinchilla animal model<sup><xref ref-type="bibr" rid="bibr5-0194599812447052">5</xref></sup> to test the ototoxicity of Drixoral, an over-the-counter preparation of oxymetazoline. Our results demonstrate that a one-time application of oxymetazoline at the time of ventilation tube insertion does not lead to demonstrable ototoxicity either functionally or morphologically, as measured by distortion product otoacoustic emission and surface electron microscopy. This corroborates the findings of Dr Isaacson, using a different model.<sup><xref ref-type="bibr" rid="bibr3-0194599812447052">3</xref></sup> Although extrapolations from animal studies to humans should be done carefully, the chinchilla animal model is an exquisitely sensitive model for toxicity as its round window membrane (RWM) is 4 to 7 times thinner than the RWM in humans, thereby allowing a much easier penetration of the toxic agents into the cochlea. It can be deduced that oxymetazoline, being safe through the thinner RWM of the chinchilla, may be also safe in the much thicker human RWM. In our study, oxymetazoline was applied only once after placement of the ventilation tube to mimic the clinical procedure whereby patients would receive drops of oxymetazoline as a hemostatic agent or to unblock the tympanostomy tube intraoperatively.</p>
<p>More knowledge will become available in the near future as to the safety of long-term/prolonged usage of oxymetazoline, as well as its direct effects on cochlear blood flow and on the electrophysiological activities of cochlear cells. Until then, the intraoperative use of oxymetazoline to unblock ventilation tubes or stop bleeding appears to be a safe and effective tool at the disposal of the otolaryngologist.</p>
<sec id="section1-0194599812447052">
<title>Disclosures</title>
<p><bold>Competing interests</bold>: Sam J. Daniel received payment for development of educational material and consultant fees from Merck (previously Schering-Plough).</p>
<p><bold>Sponsorships</bold>: None.</p>
<p><bold>Funding source</bold>: None.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599812447052">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Daniel</surname><given-names>SJ</given-names></name>
<name><surname>Akinpelu</surname><given-names>OV</given-names></name>
<name><surname>Sahmkow</surname><given-names>S</given-names></name>
<name><surname>Funnell</surname><given-names>WR</given-names></name>
<name><surname>Akache</surname><given-names>F</given-names></name>
</person-group>. <article-title>Oxymetazoline ototoxicity in a chinchilla animal model</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>2012</year>;<volume>146</volume>:<fpage>114</fpage>-<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr2-0194599812447052">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>VV</given-names></name>
<name><surname>Gaughan</surname><given-names>J</given-names></name>
<name><surname>Isaacson</surname><given-names>G</given-names></name>
<name><surname>Szeremeta</surname><given-names>W</given-names></name>
</person-group>. <article-title>Oxymetazoline is equivalent to ciprofloxacin in preventing postoperative otorrhea or tympanostomy tube obstruction</article-title>. <source>Laryngoscope</source>. <year>2005</year>;<volume>115</volume>: <fpage>363</fpage>-<lpage>365</lpage>.</citation>
</ref>
<ref id="bibr3-0194599812447052">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Isaacson</surname><given-names>G</given-names></name>
<name><surname>Buttaro</surname><given-names>BA</given-names></name>
<name><surname>Mazeffa</surname><given-names>V</given-names></name>
<name><surname>Li</surname><given-names>G</given-names></name>
<name><surname>Frenz</surname><given-names>DA</given-names></name>
</person-group>. <article-title>Oxymetazoline solutions inhibit middle ear pathogens and are not ototoxic</article-title>. <source>Ann Otol Rhinol Laryngol</source>. <year>2005</year>;<volume>114</volume>:<fpage>645</fpage>-<lpage>651</lpage>.</citation>
</ref>
<ref id="bibr4-0194599812447052">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seidman</surname><given-names>MD</given-names></name>
</person-group>. <article-title>Is oxymetazoline really safe for middle ear use?</article-title> <source>Laryngoscope</source>. <year>2005</year>;<volume>115</volume>:<fpage>1321</fpage>-<lpage>1323</lpage>.</citation>
</ref>
<ref id="bibr5-0194599812447052">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Daniel</surname><given-names>SJ</given-names></name>
<name><surname>Sahmkow</surname><given-names>S</given-names></name>
<name><surname>Akinpelu</surname><given-names>OV</given-names></name>
</person-group>. <article-title>Is ototopical nystatin ototoxic? A chinchilla model</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>2011</year>;<volume>145</volume>:<fpage>1022</fpage>-<lpage>104</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>